Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.15 | N/A | +78.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.15 | N/A | +78.57% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautiously optimistic outlook despite some market challenges. They emphasized the strength of their product portfolio.
Management highlighted strong performance in key product areas.
They noted ongoing challenges in certain markets but expressed confidence in long-term growth.
Boston Scientific's earnings report showed a significant EPS beat, indicating stronger-than-expected profitability. However, the stock fell by 4.4%, likely due to investor concerns about market challenges and the lack of revenue details. The cautious tone from management may have also contributed to the stock's decline.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WELLS FARGO & CO
Oct 17, 2011